Loading...
•
Dec 31, 2020
Reviva Q4 2020 Earnings Report
Reported financial results for 2020 and provided a corporate update.
Key Takeaways
Reviva Pharmaceuticals reported a net loss of $3.8 million for the year ended December 31, 2020. The company closed a merger with Tenzing Acquisition Corp in December 2020 and is planning a Phase 3 study of RP5063 in mid-2021, assuming fundraising goals are achieved.
Closed merger with Tenzing Acquisition Corp and publicly listed on NASDAQ Capital Market.
Plans to initiate a pivotal Phase 3 trial in schizophrenia in mid-2021, assuming fundraising goals achieved.
Completed a Phase 2 study of brilaroxazine in patients with acute schizophrenia and schizoaffective disorders.
Granted Orphan Drug Designation for brilaroxazine for the treatment of PAH and IPF.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...